查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600446

抗體藥物複合體市場：按作用機制、藥物、技術、適應症和最終用戶 - 2025-2030 年全球預測

Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

抗體藥物複合體市場2023年估值為56億美元，預計2024年將達到64.8億美元，複合年成長率為16.12%，預計到2030年將達到159.6億美元。

抗體藥物複合體(ADC) 是靶向癌症治療的一種前沿方法，它利用單株抗體的特異性將細胞毒性藥物直接遞送至癌細胞，從而最大限度地減少和減少全身暴露。對ADC的需求在於它們能夠透過精確靶向癌細胞來提高治療指數，與傳統化療相比具有顯著優勢。 ADC 主要應用於腫瘤學，但也正在考慮在自體免疫感染疾病中的應用。最終用途廣泛，包括醫院、專門的癌症治療中心和研究機構。癌症發生率的增加、生物共軛技術的進步以及研發投資的增加推動了市場的成長。關鍵的成長要素還包括臨床試驗中不斷成長的 ADC 管道以及對腫瘤生物學的更好理解。使用新穎機制和改進的連接器技術來開發 ADC 來提高穩定性和功效存在重大機會。 ADC 在非腫瘤領域也有擴大使用的潛力。然而，高開發成本、複雜的製造流程和監管障礙等挑戰是主要限制。該市場還面臨來自CAR-T細胞療法等替代療法的競爭。創新可以集中在增強有效載荷多樣性、提高瞄準精度和減少脫靶效應。研究 ADC 和免疫查核點抑制劑的聯合治療是另一種研究途徑。 ADC 市場的特點是技術快速進步和合作聯盟，凸顯了個人化醫療的趨勢。公司應優先考慮策略聯盟和許可協議，以利用生物製藥的進步。總體而言，將 ADC 的治療適用性擴展到腫瘤學之外並完善其遞送機制對於市場的持續成長至關重要，並確保 ADC 始終處於精準醫療創新的前沿。

主要市場統計
基準年[2023] 56億美元
預測年份 [2024] 64.8億美元
預測年份 [2030] 159.6億美元
複合年成長率（%） 16.12%

市場動態：快速發展的抗體藥物複合體市場的關鍵市場洞察

抗體藥物複合體市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症發生率增加
    • 臨床試驗活動的成長和強大的產品平臺
    • 鼓勵癌症研究的政府支持與舉措
  • 市場限制因素
    • ADC 製造成本上升和產品召回
  • 市場機會
    • 加大生物製藥研發投入並推出新型ADC
    • 採用先進技術進行ADC開發
  • 市場挑戰
    • ADC 製造複雜性

波特五力：駕馭抗體藥物複合體市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗體藥物複合體市場的外部影響

外部宏觀環境因素在塑造抗體藥物複合體市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗體藥物複合體市場的競爭格局

抗體藥物複合體市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗體藥物複合體市場供應商的績效評估

FPNV定位矩陣是評估抗體藥物複合體市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率增加
      • 臨床試驗活動的成長和強大的產品平臺
      • 政府對癌症研究的支持與努力
    • 抑制因素
      • 高 ADC 製造成本和產品召回
    • 機會
      • 加大生物製藥研發投入並推出新型ADC
      • 採用先進技術進行ADC開發
    • 任務
      • ADC 製造複雜性
  • 市場區隔分析
    • 作用機轉：提高ErbB2抗體（HER2）有效治療乳癌和胃癌的優越性
    • 製藥：Enhertz 作為一種有前景的腫瘤標靶治療藥物的滲透
    • 技術：優先採用無連結器技術來簡化製造流程並提高 ADC 穩定性
    • 適應症：快速使用ADC有效治療乳癌
    • 最終用戶：學術研究機構新開發的ADC新用途
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依作用機轉分類的抗體藥物複合體市場

  • CD30抗體
  • ErbB2抗體

第7章按藥物抗體藥物複合體市場

  • ADCETRIS
  • 布倫代表
  • 恩赫圖
  • 門頭
  • 帕多切夫
  • 特羅德維

第8章抗體藥物複合體市場：依技術分類

  • 可切割接頭
  • 沒有連結
  • 不可切割的接頭

第9章按適應症分類的抗體藥物複合體市場

  • 血癌
  • 乳癌
  • 淋巴瘤
  • 多發性骨髓瘤
  • 尿路上皮癌和膀胱癌

第10章抗體藥物複合體市場：依最終用戶分類

  • 學術研究所
  • 生物製藥和生物技術公司
  • 醫院
  • 專門癌症中心

第11章美洲抗體藥物複合體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太抗體藥物複合體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲抗體藥物複合體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Lonza 加強抗體藥物複合體的商業供給能力
    • CHMP 建議歐盟批准 ENHERTU 用於核准HER2 突變的晚期非小細胞肺癌患者
    • Pixis Oncology 完成對 Apexigen 的收購
    • 百濟神與 DualityBio 宣布合作推進固態腫瘤差異化抗體藥物複合體(ADC) 療法
    • 諾華支持的 Tagworks 籌集了 6500 萬美元 A 輪融資，以進一步開發 ADC 點擊發布技術
    • Lonza 收購 Synafix 以加強抗體藥物複合體產品
    • SONY與Astellas來簽署聯合研究協議，探索癌症領域新的 ADC 平台
    • BioNTech 與 DualityBio 建立全球戰略夥伴關係關係，加速固態腫瘤差異化抗體藥物複合體療法的開發
    • 輝瑞投資430億美元對抗癌症
    • Astra Zeneca與 KYM Biosciences 簽署 CMG901、claudin 18.2抗體藥物複合體授權合約
    • 美國FDA核准Trodelvy 用於治療先前接受過治療的 HR+/HER2- 轉移性乳癌患者

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • ADC Therapeutics SA
  • Ambrx Biopharma Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Byondis BV
  • Celldex Therapeutics Inc.
  • Creative Biolabs, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Heidelberg Pharma AG
  • ImmunoGen, Inc.
  • Innate Pharma SA
  • Innovent Biologics, Inc.
  • Lonza Group Ltd.
  • MacroGenics, Inc.
  • MediLink Therapeutics
  • Merck KGaA
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Oxford Biotherapeutics Limited
  • Pfizer, Inc.
  • Pheon Therapeutics Ltd.
  • Piramal Pharma Limited
  • Recipharm AB
  • Sanofi SA
  • Sorrento Therapeutics, Inc.
  • Tagworks Pharmaceuticals BV
  • Takeda Pharmaceutical Company Limited
  • Tubulis GmbH
  • Zymeworks Inc.
Product Code: MRR-657F2A76F4DB

The Antibody Drug Conjugate Market was valued at USD 5.60 billion in 2023, expected to reach USD 6.48 billion in 2024, and is projected to grow at a CAGR of 16.12%, to USD 15.96 billion by 2030.

Antibody Drug Conjugates (ADCs) represent a cutting-edge approach in targeted cancer therapy, leveraging the specificity of monoclonal antibodies to deliver cytotoxic agents directly to cancer cells, thus minimizing systemic exposure and reducing side effects. The necessity of ADCs lies in their ability to enhance the therapeutic index by precisely targeting cancer cells, providing a substantial advantage over traditional chemotherapy. ADCs find application predominantly in oncology, but potential uses in autoimmune and infectious diseases are under exploration. The end-use scope spans hospitals, specialized cancer treatment centers, and research institutes. Market growth is driven by increased cancer prevalence, advancements in bioconjugation technologies, and rising investments in R&D. Key growth factors also include a growing pipeline of ADCs in clinical trials and a better understanding of tumor biology. Notable opportunities exist in developing ADCs with novel mechanisms and improved linker technologies to enhance stability and efficacy. There is also potential for expanding the use of ADCs in non-oncological fields. However, challenges such as high developmental costs, complex manufacturing processes, and regulatory hurdles pose significant limitations. The market also faces competition from alternative therapies like CAR-T cell therapy. Innovations can focus on enhancing payload diversity, improving targeting accuracy, and reducing off-target effects. Exploring ADC combinations with immune checkpoint inhibitors offers another research avenue. The ADC market is characterized by rapid technological advancements and collaborative partnerships, emphasizing a trend towards personalized medicine. Companies should prioritize strategic collaborations and licensing agreements to leverage biopharmaceutical advancements. Overall, expanding the therapeutic applicability of ADCs beyond oncology and refining the delivery mechanisms are vital for sustained market growth, ensuring ADCs remain at the forefront of precision medicine innovations.

KEY MARKET STATISTICS
Base Year [2023] USD 5.60 billion
Estimated Year [2024] USD 6.48 billion
Forecast Year [2030] USD 15.96 billion
CAGR (%) 16.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Drug Conjugate Market

The Antibody Drug Conjugate Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer worldwide
    • Growth in clinical trial activities and robust product pipeline
    • Government support and initiatives encouraging research on cancer
  • Market Restraints
    • High manufacturing cost of ADC and incidences of product recalls
  • Market Opportunities
    • Increasing investment in biopharma R&D and introduction of novel ADCs
    • Adoption of advanced technologies for developing ADC
  • Market Challenges
    • Complexity in manufacturing of ADCs

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Drug Conjugate Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Drug Conjugate Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Drug Conjugate Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Drug Conjugate Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Drug Conjugate Market

A detailed market share analysis in the Antibody Drug Conjugate Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Drug Conjugate Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Drug Conjugate Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mechanism of Action, market is studied across CD30 Antibodies and ErbB2 Antibodies.
  • Based on Drugs, market is studied across Adcetris, Blenrep, Enhertu, Kadcyla, Padcev, and Trodelvy.
  • Based on Technology, market is studied across Cleavable Linker, Linkerless, and Non-Cleavable Linker.
  • Based on Indication, market is studied across Blood Cancer, Breast Cancer, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer.
  • Based on End User, market is studied across Academic Research Institutes, Biopharmaceutical & Biotechnology Companies, Hospitals, and Specialized Cancer Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Alaska, California, Florida, Illinois, Massachusetts, Michigan, Montana, Nevada, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer worldwide
      • 5.1.1.2. Growth in clinical trial activities and robust product pipeline
      • 5.1.1.3. Government support and initiatives encouraging research on cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
      • 5.1.3.2. Adoption of advanced technologies for developing ADC
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of ADCs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
    • 5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
    • 5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
    • 5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
    • 5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Drug Conjugate Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. CD30 Antibodies
  • 6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

  • 7.1. Introduction
  • 7.2. Adcetris
  • 7.3. Blenrep
  • 7.4. Enhertu
  • 7.5. Kadcyla
  • 7.6. Padcev
  • 7.7. Trodelvy

8. Antibody Drug Conjugate Market, by Technology

  • 8.1. Introduction
  • 8.2. Cleavable Linker
  • 8.3. Linkerless
  • 8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Indication

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Lymphoma
  • 9.5. Multiple Myeloma
  • 9.6. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Research Institutes
  • 10.3. Biopharmaceutical & Biotechnology Companies
  • 10.4. Hospitals
  • 10.5. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
    • 14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
    • 14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
    • 14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
    • 14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
    • 14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
    • 14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
    • 14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
    • 14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
    • 14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
    • 14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. ADC Therapeutics SA
  • 4. Ambrx Biopharma Inc.
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. BioNTech SE
  • 10. Bristol-Myers Squibb Company
  • 11. Byondis B.V.
  • 12. Celldex Therapeutics Inc.
  • 13. Creative Biolabs, Inc.
  • 14. Daiichi Sankyo Company, Limited
  • 15. Eisai Co., Ltd.
  • 16. F. Hoffmann-La Roche Ltd.
  • 17. Gilead Sciences, Inc.
  • 18. GlaxoSmithKline PLC
  • 19. Heidelberg Pharma AG
  • 20. ImmunoGen, Inc.
  • 21. Innate Pharma SA
  • 22. Innovent Biologics, Inc.
  • 23. Lonza Group Ltd.
  • 24. MacroGenics, Inc.
  • 25. MediLink Therapeutics
  • 26. Merck KGaA
  • 27. Mersana Therapeutics, Inc.
  • 28. Novartis AG
  • 29. Oxford Biotherapeutics Limited
  • 30. Pfizer, Inc.
  • 31. Pheon Therapeutics Ltd.
  • 32. Piramal Pharma Limited
  • 33. Recipharm AB
  • 34. Sanofi S.A.
  • 35. Sorrento Therapeutics, Inc.
  • 36. Tagworks Pharmaceuticals BV
  • 37. Takeda Pharmaceutical Company Limited
  • 38. Tubulis GmbH
  • 39. Zymeworks Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023